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Multi voxel magnetic resonance spectroscopic imaging (MRSI) is an important imaging tool that combines imaging
and spectroscopic techniques. MRSI of the human brain has been beneficially applied to different clinical applications
in neurology, particularly in neurooncology but also in multiple sclerosis, stroke and epilepsy. However, a major
challenge in conventional MRSI is the longer acquisition time required for adequate signal to be collected. Fast MRSI of
the brain in vivo is an alternative approach to reduce scanning time and make MRSI more clinically suitable.
Fast MRSI can be categorised into spiral, echo-planar, parallel and turbo imaging techniques, each with its own
strengths. After a brief introduction on the basics of non-invasive examination (1H-MRS) and localization techniques
principles, different fast MRSI techniques will be discussed from their initial development to the recent innovations with
particular emphasis on their capacity to record neurochemical changes in the brain in a variety of pathologies.
The clinical applications of whole brain fast spectroscopic techniques, can assist in the assessment of neurochemical
changes in the human brain and help in understanding the roles they play in disease. To give a good example of the
utilities of these techniques in clinical context, MRSI application in multiple sclerosis was chosen. The available up to
date and relevant literature is discussed and an outline of future research is presented.
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MRS and MRSI
Magnetic resonance spectroscopy (MRS) is a technique
used to identify and quantify metabolites in vivo, giving
chemical and quantitative information rather than
anatomical information, as in routine MR imaging. MRS
interrogates a three dimensional volume of tissue within
the body positioned in a MR scanner, to produce a
“spectrum” of information about existing chemicals and
their relative concentrations. Most applications and
technical developments of MRS have focused on the
human brain, including clinical studies and increased
understanding of the pathology of Parkinson’s disease
[1], Alzheimer’s disease [2], stroke [3] and multiple scler-
osis (MS) [4, 5]. MR spectra can be acquired from many
chemical elements. However, proton (1H) spectroscopy* Correspondence: Saadallah.ramadan@newcastle.edu.au
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used in MRS (e.g. 31P and 13C). This is because it has
the greatest gyromagnetic ratio (γ) of non-radioactive
nuclei and a high natural abundance. This sensitivity is
augmented compared to other nuclei, due to propitious
metabolite relaxation times and because several essential
brain metabolites have multiple protons.
In 1985, Bottomley et al., used a slice-selective spin-
echo excitation and frequency-selected water suppres-
sion (at 1.5 tesla (T)) to obtain the first spatially localised
human brain spectrum, at a time when spatial localisa-
tion and spectral resolution were limited [6]. Many
spatial localisation techniques were developed in the
1980s, when the technology was in its elementary stages
and faced many difficulties in implementation and effi-
ciency. Presently, the two most basic and common tech-
niques used in spectroscopy are Stimulate Echo
Acquisition Mode (STEAM) [7, 8] and Point RESolved
Spectroscopy (PRESS) [9, 10] which are based on three
slice-selective pulses applied in orthogonal planes.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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an organ, e.g. brain, by giving a spectroscopic signature
from each part of this organ. It is a method used to
collect spectroscopic data and spatial distribution of me-
tabolites using multiple-voxel locations within a single
measurement. Multi-voxel spectroscopy (2 or 3 dimen-
sional (2D or 3D)) plays a particularly prominent role,
not only in increasing the spatial coverage, but also in
improving the efficiency of data collection. Major disad-
vantages of the technique are long acquisition times,
lack of adequate signal-to-noise ratio (SNR), insufficient
water and lipid suppression and limited spatial coverage;
these elements pose major constraints and limitations.
Despite these disadvantages, MRSI has the potential to
play a significant role to assist in clinical diagnosis and
treatment planning. Many different MRSI acquisition
methods have been developed, including conventional
and fast MRSI methods, each of which has its own
advantages and disadvantages.
MRSI was initially conceptually proposed and imple-
mented in a phantom with varying phosphorus chemical
shift composition by Brown et al. in 1982 [11] . The method
used a sequence of radio-frequency (RF) and magnetic field
gradient pulses to measure chemical shift distribution
across a rectangular grid. Simple Fourier transformation
was applied to recover the original chemical shift distribu-
tion. The first in vivo application was carried out on a
human forearm on a 1.5 T magnet by Pykett et al. [12].
Multiple sclerosis (MS)
MS is an immune-mediated neuronal disorder in which
inflammatory cells attack the myelin of the central
nervous system (CNS), leading to varying extents of neu-
roaxonal injury, demyelination and gliosis by affecting
both the brain and spinal cord [13, 14]. Typically, symp-
toms of MS are based on the location of the plaque and
most patients experience initially exacerbations and
remissions due to inflammation and recovery with
remyelination which, in the later stages, is exhausted
and then leads to persistent symptoms. Clinically, MS
can be classified into: (a) relapsing remitting MS (RRMS)
that accounts for 85% of MS patients, and is charac-
terised with remission phases (stability) and relapse or
exacerbation [15], (b) chronic progressive MS is divided
into primary progressive MS (PPMS), secondary pro-
gressive MS (SPMS) and progressive relapsing (PRMS).
However, the new classification by Lublin [16] aims to
characterise progressive disease according to its clinical
and MRI activity. PPMS is defined by slowly progressing
disability from onset, characterised by localised subpial
inflammation without blood brain barrier disruption
[17]. The diagnosis and management of MS is increas-
ingly reliant on non-invasive MR modalities. Indeed, the
current diagnostic criteria for MS [18] includes specificMR imaging features which provides evidence of dissem-
ination in space and time of brain and spinal cord
lesions. Recent guidelines regarding the frequency of
MRI protocols and frequency of MR evaluations [19]
suggest MR imaging be undertaken between every
6 months and 2 years for all RRMS patients, to monitor
new and enhancing lesions and contribute to the med-
ical management of the relapsing form of the disease.
However, in contrast, there are no current reliable
markers to evaluate therapeutic efficacy in the progres-
sive forms of MS, which has been a major obstacle in
the development of new disease-modifying therapies.
1H-MRS might add to the specificity of diagnosis and
clinical management by the potential identification of
new disease biomarkers [20, 21]. 1H-MRS provides a
unique potential to evaluate biochemical alteration in
MS. In light of this, neurochemical changes of the brain
are related to the metabolite concentration levels. For
instance, a reduction of N-acetylaspartate (NAA) level,
which is an amino acid derivative and has a high con-
centration in the brain, reflects axonal degeneration or
loss, [20, 22] while increased Creatine (Cr) levels, known
to play an important role in cellular energy metabolism,
can be indicative of gliosis in MS patients [23]. Further-
more, increased resonance intensity of Choline (Cho)
indicates an altered turnover of cell membranes level in
steady state, and finally, alteration in myo-inositol (mI)
concentration can indicate increased glial cell activity or
changes in the inflammatory cells [24].
While existing MR protocols used in MS focus on
changes in white matter lesions it is evident that there is
a disparity between lesion load and clinical disability
[25] and current MR protocols have limited sensitivity in
detecting changes in gray matter. This leaves neuroradi-
ologists with the dilemma on how to best accurately
evaluate pathological changes occurring across the entire
MS brain [26].
Several reports have primarily studied MS patients using
single-voxel spectroscopy (SVS) methods to evaluate spec-
troscopic changes of brain metabolites and their ratios in
several ROI including normal appearing white matter
(NAWM) and (gray matter) GM [27, 28], in addition to
whole brain NAA (WBNAA) [29] at different fields
strengths (1.5–3 T) and echo time (TE) values (20–70 ms)
[30]. However, these techniques have successfully col-
lected data from a limited region of the brain, within ac-
ceptable acquisition times, the real challenge for these
methods is to be able to perform a metabolite mapping
covering the whole brain, with high spatial resolution and
short TE in order to estimate neurochemical changes
within larger brain regions in one session. The potential
usefulness for such techniques in a clinical setting is also
dependent on the acquisition time for the MRS or MRSI
profile. If the intention is to run these novel MR metrics
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times and quantification procedures need to be optimised
to make this application feasible.
Scope of the review
In this article, the underlying principles of MRS will be
described and the different MRSI techniques compared,
focussing on recent advances in high-speed MRSI
methods. MS will be used as an example pathology in a
clinical setting where MRSI techniques are being applied
to map brain metabolic changes in different areas of the
brain and at different disease stages to evaluate the po-




In general, the spatial coverage of MRS falls into two
categories, either localised SVS or multi-voxel MRSI
[31]. The performance of these techniques is based on a
slice-selective excitation of RF pulses in variant forms,
combined with magnetic-field gradients. The primary
principle of SVS is that it sequentially excites three
orthogonal slices, whose intersection defines the volume
of interest (VOI). Then the generated echo signal is ac-
cumulated so that only the signal from the voxel, where
all three slices intersect, survives. To ensure signal fidel-
ity, signals from outside the VOI can be eliminated by
dephasing crusher gradients and phase cycling of RF
pulses [32]. In SVS techniques, STEAM or PRESS are typ-
ically used to excite the VOI within the brain as a standard
method of clinical imaging [33]. Figure 1 shows that
single-voxel localisation methods collect signals from a
rectangular region of interest (ROI). PRESS (Fig. 1a) uses
a double echo technique; where the procedure consists of
an initial 90° RF pulse applied with an x-gradient to excite
a slice followed by second and third 180° RF pulses
applied with two other gradient pulses along y and z
planes, respectively. Also, appropriate spoiler gradientsFig. 1 Two single-voxel localisation methods: a the PRESS sequence; b the
gradient pulses are indicated by black, green and red colours in the schemaalong all gradient channels are used to dephase undesired
coherence. In STEAM (Fig. 1b), however, three 90° RF
pulses are used in order to obtain the stimulated echo.
Accompanying this operation, a large spoiler gradient
pulse should be employed to dephase other created signals
during the mixing time (TM). A second 90° RF pulse is
applied after half of TE from the first 90° RF pulse. In order
to eliminate any undesired signals, spoiler gradients need
to be carefully applied during TE on all gradient channels.
To determine which sequence is to be selected is largely
dependent on the specific metabolites to be detected in
the study. STEAM uses symmetric RF pulses and opti-
mised gradient waveforms to minimise TE, so it is applic-
able to instances that require short TE values for the
retention of metabolites with short T2. PRESS accommo-
dates the requirements for studies that have a preference
for longer TE and it comes with higher signal yield due to
the 180° RF pulses used [8, 34]. PRESS can still be used in
cases where T2 is long and T2* (T2 with static magnetic
field (Bo) inhomogeneity contributions) is short. Figure 2
shows typical single-voxel spectra acquired on a 3 T
Prisma scanner (Siemens, Erlangen) at different TE value.
Conventional multi-voxel techniques
Single-voxel techniques are invariably used in clinical
settings, however, SVS techniques are restricted by their
limited coverage and coarse spatial resolution. These
constraints can be overcome by MRSI techniques [11].
For more global coverage, MRSI can also be extended to
3D-MRSI [35–37].
The conventional 2D- and 3D-MRSI studies of the
human brain, which are usually based on PRESS se-
quence, have numerous challenges which include long ac-
quisition times, low SNR and extra-voxel contamination.
Scan time is proportional to number of phase-encoding
steps, repetition time (TR) and number of averages [8, 38,
39]. Although PRESS-MRSI was designed for routine
scanners, the scan times were still too long for clinical
applications especially in 3D mode [40]. In addition toSTEAM sequence. Note that the three orthogonal slice-selective
tic representation. Reproduced with permission from [39]
Fig. 2 Signal obtained from prefrontal cortex (PFC) of voxel size (1.5 cm3) from a healthy subject: a at short TE and b at long TE using PRESS
approach on a 3 T scanner (Prisma, Siemens, Erlangen)
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comes an important issue especially when PRESS-MRSI is
used to map whole brain. For the latter issue, for example,
higher order shimming was developed to improve the field
homogeneity for larger volumes [41]. Other MRSI issues
have been expanded upon elsewhere [38]. Figure 3 shows
an example of 2D PRESS-MRSI data at 3 T [39].
To overcome the above challenges, fast MRSI tech-
niques were introduced as an improved alternative to fa-
cilitate implementation of this technique in the clinic,Fig. 3 MRSI data acquired from a 3-year-old girl with an idiopathic develop
(TE: 135 ms) in the axial plane with voxel size of 1.5 cm3. Reproduced withand to eliminate challenges associated with conventional
MRSI techniques.
Parallel imaging
Parallel imaging techniques, such as sensitivity encoding
(SENSE) [42], simultaneous acquisition of spatial har-
monics (SMASH) [43] and generalised auto-calibrating
partial parallel acquisition (GRAPPA) [44], have been in-
troduced and commonly used to accelerate MRI tech-
niques and can also be applied to improve the temporalmental delay. Data was acquired using a 2D PRESS-MRSI at 3 T
permission from [39]
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imaging, signal sensitivity and spatial encoding can be
improved by using multiple receiver coils, whereby the
number of needed k-space lines decreases with consider-
able acceleration in the image acquisition.
For SENSE-MRSI, the principal balance between ac-
celeration of spatial encoding and noise amplification is
an essential requirement due to two factors; the reduced
number of phase-encoding steps, and the acceleration
factor (R). It has been proposed that low SNR can be im-
proved in parallel imaging based techniques by increas-
ing the number of coil elements [48]. For example, the
performance of SENSE based 2D-MRSI can be improved
using an 8–12 channel-coil [47], and SENSE based 3D-
MRSI using a 32 channel coils [49]. An important add-
itional advantage of parallel imaging techniques is their
compatibility with fast MRSI approaches discussed
below. Figure 4 shows an example of a SENSE-MRSI
data with an acquisition time of only 3.37 min [50].
Fast multi-voxel techniques
In order to study the whole brain, there must be a de-
crease in the scanning time and motion sensitivity. MRSI
methods can be accelerated using time-varying gradients
during the readout of spectroscopic imaging data [51–
54]. Efficient spatial and spectral k-space sampling with
time-varying gradients is a mechanism that can be used
to address time limitations. The majority of k-space tra-
jectories that are widely used in spectroscopic imaging
are echo-planar and spiral trajectories [55–57]. Recent
developments in the gradients hardware design made it
possible to traverse the k-space within a shorter period
of time within each repetition [58]. For this reason,
spiral imaging has shown to be useful in specificFig. 4 Illustrates the data spectroscopy and mapping of brain metabolite of c
acquisition methods (bottom line) of a voxel in tumorous tissue and b healthy
and acquisition data parameter (TE/TR: 228/1500 ms), slice thickness (20 mm) aapplications such as cardiovascular and functional brain
imaging applications [59].
A number of fast MRSI acquisition techniques de-
signed to collect k-space data in three spatial dimensions
have been reviewed elsewhere [48, 60]. Their main aim
is not only to reduce acquisition time but also to minim-
ise voxel signal contamination and improve metabolite
mapping of the whole brain [61].
Many different strategies for fast MRSI have been used
to gain high spatial resolution and to improve the time
efficiency of MRSI experiments. The most common and
effective of these approaches applied to the human brain
are briefly described in this article.
Spiral MRSI
Spiral MRSI is a fast spectroscopic imaging technique
that traverses k-space by spiral trajectories. Oscillating
readout gradients are applied in a spectroscopic imaging
sequence in two spatial dimensions during the data
acquisition. These gradient waveforms (Gx, Gy) rapidly
traverse spiral trajectories in two directions of k-space
(kx, ky). These trajectories can be fully or partially
covered within one TR as shown in Fig. 5.
Due to this ability, a sequence with spiral trajectory
has a much quicker acquisition time compared to con-
ventional MRSI methods [58]. This single-shot spiral-
imaging technique sets a remarkable new standard for
fast spectroscopic imaging.
Spiral MRSI was originally introduced by Adalsteinsson
et al. [56] to evaluate the neurochemical change of metab-
olites in GM in patients with SPMS [4]. However, this
technique has limitations in certain clinical applications
(i.e. increased blurring and hardware limitation), and thus
never became a widely used tool despite its advantages.onventional MRSI methods (top line) compared with SENSE-MRSI
tissue; with an acquisition time of (14.02 min) and (3.37 min) respectively,
nd FOV (220 mm). Reproduced with permission from [50]
Fig. 5 a In a spiral MRSI, two time-varying readout gradients are administered in the data acquisition period with oscillating spiral trajectories. b
Outlines the projection of a k-space trajectory along the kf axis. The spiral trajectories originate from the (kx, ky) plane and repeatedly run a path
through the kx, ky, kf spaces with multiple and simultaneous spiral trajectories increasing volumetric acquisition around the kf axis. Reproduced
with permission from [39, 56]
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are usually non-uniform, and thus acquired data has to be
re-gridded to reconstruct the data onto a Cartesian k-space,
where Fourier transformation can be applied [57, 59]. Due
to the data collection being completely symmetric and sam-
pled around the centre of k-space, several artefacts that are
influenced by external variables such as motion or other
instabilities are reduced [62]. As a result spiral MRSI offers
shorter imaging time, higher spatial resolution, improved
point spread function (PSF) and SNR.
Spiral spectroscopic imaging can be readily and effect-
ively combined with other imaging-based techniques
such as parallel imaging methods leading to Mayer et al.
proposing their accelerated version of this technique for
human brain at 3 T [63].
Recent work focussed on improving localisation and
spectral quality of spiral MRSI [64–66]. These develop-
ments will have significant clinical impact on the study
of human brain. Despite spiral MRSI having several ‘the-
oretical’ benefits, its major drawback is the high strain
on gradient hardware as a result of its demanding trajec-
tory design [58]. An example of the clinical application
of the spiral MRSI at 3 T, with a data-acquisition time of
13.5 min, is shown in Fig. 6.
SENSE-based spiral MRSI [63] has been applied to
address the challenges associated with their clinical ap-
plication, e.g. volumetric coverage and evaluation of the
neurochemical change of the whole human brain [67].Turbo spectroscopic imaging (turbo-MRSI)
MRSI can also be accelerated by multiple-echo refocus-
sing which is analogous to turbo-spin-echo imaging as
seen in Fig. 7. Determining the efficiency of this data
collection strategy is largely dependent on rapid acquisi-
tion time and spatial resolution without signal loss of
brain metabolites [68]. Turbo-MRSI techniques have
proven successful in the past in detecting major brain
metabolites such as NAA, Cho and Cr within an accept-
able acquisition duration at 1.5 T [69]. Stengel et al. has
succeeded in reducing the acquisition time to 6 min by
using turbo-MRSI with four phase encodes per TR to
study stroke patients [70].
Even though turbo-MRSI techniques have successfully
mapped and assessed uncoupled brain metabolite distri-
butions with long TE, mapping of coupled resonance me-
tabolites (e.g. glutamine + glutamate (Glx)) proved to be a
challenge. Fortunately, Yahya et al. [71] proposed modifi-
cations that allow the quantitation of Glx at TE of 100 ms
and 170 ms in addition to halving acquisition time.
Turbo-MRSI can be combined with parallel imaging
techniques such as SENSE to improve acquisition rate to
obtain higher resolution (high sensitivity). Dydak et al.
was able to design a turbo-SENSE-MRSI sequence that
uses an echo train length of four to acquire spectro-
scopic data within two to three minutes and reduced
acquisition times by about eight folds compared to
conventional MRSI techniques [50].
Fig. 6 Displays the spectral data from three slices using a spiral MRSI technique at 3 T (TE/TR: 144 ms/2 s, FOV: 8 × 9 × 6 cm) using a 32-channel
phased array head coil. Reproduced with permission from [58]
Fig. 7 Readout strategy for Turbo-MRSI sequence using spin-echo
imaging per excitation preceded by water and lipid suppression
(CHESS and outer-volume suppression (OVS)). Reproduced with per-
mission from [39]
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parallel imaging techniques, high spatial resolutions
MRSI become clinically feasible. Many challenging clin-
ical applications have been achieved through the use of
the turbo-SENSE-MRSI technique [72] involving high
spatial encoding train (i.e. long multiple-echoes train)
which only becomes feasible at 3 T. For instance, acqui-
sition times are significantly reduced (~1 min) to obtain
brain metabolites ratios Cho/NAA and Cr/NAA with a
TE of 144 ms, even though SNR is reduced because of
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cesses, turbo-MRSI techniques [73] have made it possible
to evaluate brain metabolite levels within the pons, accu-
mulating spectroscopic data within very short periods of
time (1 min 20 s) using long TE (288 ms) at 1.5 T.
The advent of the turbo-MRSI technique has made fas-
ter data acquisition possible, although with a major draw-
back of lowering spectral resolution, due to the short time
between consecutive refocusing pulses [70, 73]. The
second disadvantage is the drop in SNR as a consequence
of the increase in spatial encoding trains of more than
two, as the spatial encoding maintains a balance between
the output of acquisition scan time and SNR [50, 72].
Echo-planar spectroscopic imaging (EPSI)
The introduction of echo-planar imaging (EPI) originally
proposed by Mansfield [74] has facilitated the develop-
ment of EPSI on conventional clinical MRI scanners.
The latter technique made the mapping of spatial me-
tabolite distributions in the brain possible, accelerating
spectral data acquisition compared to conventional
MRSI, therefore creating an exceptionally fast imaging
technique. New improvements to the readout frame of
EPI techniques meant that an oscillating readout gradi-
ent can be reproducibly used in EPSI. EPSI encoding
method that uses multiple-slice or PRESS excitation in
2D or 3D-MRSI [75, 76] became the method of choice.
These improvements led to the advent of EPSI to change
how MRSI is applied in a clinical setting.
In the last decade, EPSI were widely used to acquire
MRSI data in a shorter scanning time by encoding
spatial and spectral dimensions in a single readout gradi-
ent (Fig. 8a). This fact is based on rapid k-space sam-
pling per excitation that allows planar data collection on
rectilinear trajectories (Fig. 8b).
Echo-planar encoding has proved particularly useful in
1H-MRSI applications. Its application has improved per-
formance in covering large volumes due to its improved
spatial and temporal resolution, compared to typical
conventional phase-encoded MRSI.
The spectroscopic images for distribution of the major
metabolites in the human brain were first obtained with
3D-EPSI technique by Posse et al. [75] and later with
fully automated analysis by Ebel et al. [76]. A compari-
son between EPSI and conventional MRSI spectra indi-
cated a similarity in SNR per unit volume and unit time
[60, 77]. However, an outstanding feature of the two-
dimensional EPSI method [55] is the improvement of
spatial resolution and SNR for a number of metabolites
at short TE (13 ms) and acquisition time (64 s). In
addition to evaluating and detecting the three major me-
tabolite maps (NAA, Cho, Cr), 2D-EPSI was also applied
to measure the changes in brain lactate at long TE
(272 ms) and 1.5Tesla [78].3D-EPSI was implemented by Maudsley et al. [79]
in mapping the distributions of the three major me-
tabolites (NAA, Cho, Cr) over a wide region of the
human brain at intermediate TE (70 ms) where me-
tabolite ratios and average metabolite values in GM
and white matter (WM) were clinically determined on
a 3 T MRI scanner. MRSI data processing was carried
out by a fully automated processing approach (Metab-
olite Imaging and Data Analysis System (MIDAS))
[80]. Metabolite maps obtained from volumetric EPSI
technique with an acquisition time of 26 min are
shown in Fig. 9.
New EPSI methods were developed where the quantity
of k-space lines are reduced. When 2D-spatial selective
RF (2DRF) are incorporated within EPSI sequences, a
new type of 2DRF-EPSI is obtained [81]. 2DRF-EPSI ad-
dresses the poor image quality that results from artefacts
and low spatial resolution, by shortening echo-train
length, and doubling the spatial resolution along the
direction of phase-encoding.
The implementation of EPSI techniques at high field (3
to 7 T) has enabled not only to linearly gain SNR per unit
volume and time but has also allowed for the evaluation
of J-coupled metabolites such as glutamate (Glu) and glu-
tamine (Gln) [48]. 3D-EPSI was successfully applied to as-
sess the concentrations of major metabolites, including J-
coupled, at 4 T and 3 T in GM and WM [53] of healthy
volunteers. This is an important development as it has
greatly increased the spectral resolution and SNR associ-
ated with shortened experimental time (<10 min) and has
thus sparked interest in clinical studies of MS and stroke
for the potential benefits of this methodology [53].
Short TE EPSI was recently introduced by Ding et al.
[82] to evaluate the neurochemical variation of major
metabolites as well as Glx and mI in conjunction with
parallel imaging acquisition. NAA, tCr, Cho, Glx and mI
were found to have different mapping concentrations in
WM and GM in comparison with other short TE
(15 ms) studies [49]. Mapping of whole brain metabo-
lites was also achieved by implementation of 3D-EPSI at
short TE (20 ms) [83]. An improvement in short TE
EPSI applications with high spatial resolution and im-
proved SNR was increasing spatial sensitivity using
multiple coils [84, 85].
The significant development of advanced gradient
hardware has resulted in the emergence of a new EPSI
method that focuses on high spatial resolutions with a
large coverage of the human brain at 3 T. The flyback
3D-EPSI technique [40] was presented to improve the
spatial resolution and SNR for different metabolites
(NAA, Cr, Cho and lactate). Zierhut et al. employed
flyback EPSI for a detailed analysis of the data from a
human glioma patient with an acquisition time of less
than 9.5 min, with a spatial resolution of 1 cc [40].
Fig. 8 a EPSI sequences are applied to encode localised spectra with a single readout gradient. b k-space trajectories of echo-planar spectroscopic
imaging indicate data acquisition in one TR of the pulse sequence during spectral encoding. Reproduced with permission from [39]
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shown that the efficiency of spatial and spectral encod-
ing can be improved by applying volumetric EPSI tech-
niques. However, these improvements are still limited by
long acquisition times, which are considered to be a cru-
cial factor in many clinical studies [86]. The first modifi-
cation to enhance the acceleration of data collection was
the use of SENSE-EPSI. This strategy combined theFig. 9 Whole brain mapping and a spectrum of major metabolites, mean w
3 T from a healthy subject (TE/TR = 70/1710 ms), total acquisition time (26
volume (0.31 cm3). Reproduced with permission from [48]spatial and spectral encoding capabilities and has been
investigated by Lin et al. [87] to obtain major brain me-
tabolites maps. In this particular study, the data acquisi-
tion time was halved to 32 s for 32 × 32 image matrix
with high spatial-temporal resolution, using SENSE
acceleration factor of two. However, SNR declines with
faster acceleration, which can affect the usefulness of
these techniques clinically. 3D-EPSI and 2D-SENSE [49]ater-reference spectroscopic imaging (SI H2O Reference) using EPSI at
min), k-space points (50 × 50 × 18), FOV (28 × 28 × 18 cm3) and voxel
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that covers the whole brain in a shorter acquisition time
(1 min) for 32 × 32 × 8 spatial matrix and TE (15 ms) at
high field (3 T).
Another method that can be used to map metabolite
distribution in the whole brain is the 3D GRAPPA-EPSI
techniques [88]. The spectral quality, brain metabolite
concentrations and SNR values from 3D GRAPPA-EPSI
were obtained with an acceleration factor of 1.5 shows
similar results to the 3D-EPSI technique [88]. Reduction
of SNR has become a major challenge for implementing
2D GRAPPA-EPSI [89] techniques with a 32 channel
coil array [53], which improves SNR values due to the
large numbers of small sized coils [90]. In addition to
this, 2D GRAPPA-EPSI allows for the mapping of most
metabolites within a much shorter time.
Dydak et al. incorporated the MEscher-GArwood
(MEGA) editing scheme [91] within the EPSI technique
[92, 93] for mapping of the main inhibitory neurotrans-
mitter γ-aminobutyric acid (GABA) levels. The MEGA-
EPSI method can perform data acquisition of GABA
level activity in less than 10 min in a 2D slice. The short
acquisition time and high sensitivity of the 2D MEGA-
EPSI lead to the creation of 3D MEGA-EPSI technique
due to its increased spatial resolution with an acquisition
times of 17 min for eight slices at 3 T, which is a major
improvement compared to other techniques [94].
Recently, image quality and brain metabolites concen-
trations have been studied by applying a commonly
reduced k-space strategy at 3 T. For this purpose, the
GRAPPA-EPSI technique was introduced by Sabati et al.
[84] to improve the spectral quality associated with
accelerated acquisition of volumetric EPSI data. This has
resulted in an of experimental time of 16 min at the
expense of SNR values [40]. The results obtained from
3D-EPSI techniques are compared to the GRAPPA-EPSI
technique in Fig. 10.
A further benefit to the EPSI technique is its flexibility to
adapt to a wide range of techniques to improve speed of
data collection in certain specialised areas across a wide-
range of MRSI and MRI techniques, including: Flyback,
GRAPPA, and SENSE in 2D and 3D modes, that would
otherwise be relying on slow conventional MRSI methods.
Some disadvantages regarding EPSI need to be men-
tioned. The speed of data collection is the root cause for
EPSI’s major technical problems with the gradient system,
especially when recording data with disequilibrium of
positive and negative gradient lobes [38]. This leads to
further contraction of spectral bandwidth which poses a
problem considering EPSI has less SNR than traditional
phase-encoded MRSI. Therefore, multiple averages are
required to improve SNR. Regardless, when the above
challenges are suitably addressed, EPSI can be considered
one of the best techniques for whole brain 3D-MRSI [76].Comparison of MRSI techniques
Advances on MRSI techniques have focussed on either
improving the temporal resolution or investigating the
relationship between spatial resolution and SNR. To
achieve these aims, work has been carried out to im-
prove the MRSI techniques and increase spatial coverage
e.g. 2D-3D MRSI.
Detecting various brain metabolites in vivo, using
different parameters for 3D PRESS-MRSI [36, 40],
showed variable NAA concentrations in different acqui-
sitions at 3 T. Recently, the 3D PRESS-MRSI has been
improved by using 4 slices in PRESS box and outer vol-
ume suppression pulses to cover the whole brain with
an acquisition time of 9 min, leading to spectral data of
NAA, Cho and Cr [37]. Multiple 2D-MRSI has signifi-
cant improvements for spatial resolution, SNR and
whole brain metabolite mapping at long TE [95].
A summary of the results of various MRSI methods
are shown in Table 1. Data shown represents measured
metabolites from healthy controls (HCs) using PRESS-
MRSI with different parameters.
Improvements in spatial coverage and temporal
resolution have been achieved by using novel MRSI
techniques as shown in Table 2. High speed EPSI was
used at short TE (15 ms) to find out that in HCs Glu
(12.8 ± 1.5 mM) in GM is of a significantly higher
concentration than in WM (7.0 ± 1.1 mM) and also
higher than other brain metabolites like NAA (8.6 ±
0.7 mM) and mI (6.3 ± 0.7 mM) in GM in HCs [53].
These improvements in temporal resolution due to
GRAPPA enabled by higher number of coil elements
(32 channel) [89] make this technique suitable for
clinical studies with acceptable acquisition times.
Whole brain has also been studied by using EPSI tech-
niques at short TE (17.6 ms) to measure the brain me-
tabolite in both GM and WM of brain. The results
showed that the value of NAA concentration (12.05 ±
0.47 mM) is higher in the parietal lobes in GM than
NAA concentration (8.74 ± 0.34 mM) in WM [82].
Whole brain was also studied by GRAPPA-EPSI
short TE technique, where NAA (15.36 ± 2.62), mI
(6.11 ± 1.14), tCr (11.97 ± 1.67) and Glx (18.40 ± 3.19)
mM where found to be more abundant in GM than
WM [89]. In addition, GRAPPA-EPSI sequence at TE
of 70 ms [84] found that WM NAA concentration to
be (595 ± 37.9) which is higher than Cr (346 ± 23.9)
and Cho (100 ± 9.7) institutional units (IU) for HCs.
A summary of fast MRSI studies in human brain and
their results are shown in Table 2.
MRSI in multiple sclerosis
MRSI was applied to MS patients at 1.5 T with long TE
values [96–99] and at 2 T with short TE values [100].
Some studies focused on lesions compared to NAWM
Fig. 10 Illustrates the comparison between two fast MRSI sequences at 3 T: a the 3D-EPSI and b GRAPPA-EPSI sequences, to show the whole
brain mapping of metabolites with interleaved water reference acquisition (SI H2O Reference) from a healthy normal subject at intermediate TE
(70 ms). Reproduced with permission from [84]
Al-iedani et al. Journal of Biomedical Science  (2017) 24:17 Page 11 of 19and GM [14]. Other studies compared distinct different
clinical groups such as RRMS [101, 102], SPMS and
PPMS [103, 104].
Conventional MRSI techniques have identified changes
in metabolite concentration in limited regions within
NAWM or GM affected by the disease process [105–
107]. For this purpose, Tiberio et al. used 3D PRESS-
MRSI at TE of 30 ms and 1.5 T. Statistically significant
metabolic differences between RRMS patients and HCs
were found in NAWM total NAA and cortical gray mat-
ter (CGM) Glx and Cho [107]. This technique was also
used at TE of 40 ms and 3 T by Ratiney et al. [108] to
investigate mI concentration level in normal appearing
white and gray matter (NAGM). mI concentration was
significantly increased in both NAWM and NAGM of
MS patients compared to control subjects. Changes in
the above metabolites have been associated with clinical
impairment or/and neuronal dysfunction in MS patients.
In another study, RRMS patients and age-matched
controls were recruited to investigate abnormal meta-
bolic changes in GM and WM by using conventionalTable 1 Brain metabolite concentration and acquisition time of vari
Methods TE/TR (ms) Metabolite (mM)
3D PRESS-MRSI 144/1100 NAA: 10.1 ± 0.64
3D PRESS-MRSI 144/1100 NAA: 6.9 ± 1.3, Cho: 6.5 ± 1.4 Cr: 6.1 ± 1.2
3D PRESS-MRSI 144/1100 Cho/NAA:(0.51–0.54)
Multiple 2D-MRSI 144/ 2300 NAA:2.5 ± 4.47, Cho:2.94 ± 9.71, Cr:7.3 ± 4.09
2D-MRSI 135/1500 MS patients: NAA:9.48 ± 0.73





Abbreviations: aTacq acquisition time, bNR Not reported3D-MRSI techniques at 3 T [102]. With an MRSI scan
lasting 34 min, it was found that the concentrations of
Cr, Cho and mI in WM of RRMS group were higher
(p ≤ 0.01) compared to controls, while WM NAA was
lower (p = 0.07). NAA reduction reflects neuronal and
glial loss or impairment at early stage of RRMS, whereas
brain inflammation leads to increase of mI and Cr con-
centration levels due to intense gliosis. Additionally, in-
crease in Cho levels is usually associated with abnormal
membrane turnover from myelin breakdown.
Suhy et al. [104] found that NAA was reduced in
RRMS and PPMS from NAWM compared to HCs WM.
Similarly, the normalized value of brain metabolites in
NAWM of RRMS and PPMS patients shows that there
is a significant decrease in NAA/Cr ratio (p = 0.027).
These results were achieved by applying a 2D PRESS-
MRSI at long TE (135 ms) at 1.5Tin RRMS and PPMS
groups. However, by applying a 2D PRESS-MRSI at TE
(135 ms) at 3 T no statistically significant difference of
absolute concentrations of Cr, NAA and NAA/Cr
ratio was found in NAWM between RRMS vs controlous MRSI techniques
Tacq (min)a Brain region/ FOV/ voxel size/Bo (Tesla) Ref.
21.12 Centre of brain/ 12 × 12 × 8 cm3/1 cm3/3 T [40]
17 Not reported/ 12x12x8 and 16x16x8 cm3/1 cm3/3 T [36]
21.12 Not reported/ 12 × 12 × 8 cm3/ 1 cm3/3 T [46]
26 Whole brain scans/ Not reported [95]
NRb WM and GM/ 16 × 16 cm2/ 2 cm3/1.5 T [112]
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NAA/Cr (p < 0.0003 and p < 0.001) in SPMS compared
to RRMS and control groups. The above work sug-
gested reduction in NAA and NAA/Cr as potential
indicators for irreversible damage in MS. NAA Re-
duction is usually associated with neuroaxonal injury.
Astrocytic proliferation reflects increased levels of Cr.
NAA and NAA/Cr are constantly reported with lower
level values from NAWM and lesion of MS patients.
Recently, Khan et al. showed that tNAA/tCr (1.88 ±
0.19 mM, p < 0.05) has strong and statistically signifi-
cant inverse correlation with total disability score in a
group of 39 RRMS patients [110].
Spectroscopic data from early RRMS in NAWM,
CGM and lesions have been reported by Kapeller
et al. [111]. This study focused primarily on quantify-
ing the concentration of the NAA, Cr and mI using
PRESS-MRSI technique at short TE (30 ms). LowerFig. 11 Shows the spectra of voxels in a GM and b WM of healthy and PP
respectively and e, f: acquired from GM and WM regions of a PPMS patien
(16 × 16 cm2, yellow border) and VOI (8 × 8 × 2 cm3, white border). ReproducNAA concentration (p < 0.01) was found in RRMS in
CGM and NAWM compared to controls. Shorter TE
is more sensitive to coupled metabolites than longer
TE spectroscopy.
A PPMS group was studied by Sijens et al. at long
TE (135 ms) by using 2D PRESS-MRSI [112]. Results
from the brain metabolic maps from PPMS patients
confirmed that Cr levels were elevated, whereas NAA
and Cho concentrations were decreased in WM more
than in GM in PPMS compared with controls. The
bigger decrease of NAA and Cho in WM is expected
as a result of the larger presence of myelin in WM
than in GM [112]. Figure 11 depicts brain sample
spectral data from PPMS patients and controls in GM
and WM [112].
Recently, in vivo proton MRSI technique at long TE
(135 ms) and 3 T has been reported by Rahimian et al.
[113] not only to measure brain metabolite concentrationMS subjects: c, d acquired from healthy subject in GM and WM,
t, respectively. Experimental parameters: TE/TR = 135 ms/1500 ms, FOV
ed with permission from [112]
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and PPMS groups but also to differentiate between MS
subtypes. Comparing the results obtained shows that there
was a significant increase in Cr concentration in non-
enhancing lesions of RRMS patients compared to the
PPMS patients (p = 0.008) whilst the concentration of
NAA/Cr was significantly reduced (p = 0.03) in PPMS
compared with RRMS. However, there was no statistically
significant difference in concentrations of Cho, NAA and
NAA/Cho between the two groups.
EPSI allowed detection of neuro-metabolites in the
visual tract WM of MS patients [5]. In this study, EPSI
was used to study neurochemical changes at 1.5 T
associated with visually evoked potential (VEP) abnor-
malities. It was found that the average value of NAA is
significantly lower (p ≤ 0.05) in the abnormal VEP
group than in the normal VEP group. 3D-MRSI was
implemented using EPSI techniques at 1.5 T [114] to
measure the major metabolite ratios in control and MS
cohorts from two ROIs: supratentorial brain and cen-
tral brain. This study was performed at long TE
(144 ms) on three subtypes of MS: RRMS, PPMS and
SPMS, where it was found that NAA/Cr ratio was
significantly decreased (p < 0.01) for all MS cohorts
compared to HCs in both ROI. Sample spectroscopic
data from SPMS patients are shown in Fig. 12.
The multi-slice EPSI technique was introduced by
Mathiesen et al. [86] as a response to the limitations of
VOI in conventional MRS techniques. The introduction
of this technique made it possible to measure brainFig. 12 Spectroscopic data from a typical SPMS brain from three separate
represented by the numbers and red spots. Experimental parameters: 3D-EP
(24 × 24 × 8 cm3) and slice thickness (4 mm) at 1.5 T. Reproduced with permetabolites in specific regions such as MS lesions,
NAWM, CGM and to estimate WBNAA which is gener-
ally considered an indicator of disease progression and
treatment efficiency. Decreases in global ratios (NAA/Cr
and Cho/Cr) were noticed for early MS patients com-
pared with healthy subjects, however, no statistically sig-
nificant differences were noticed in NAA/Cr between
these two groups [86].
Due to the capabilities of multi-slice EPSI technique
to cover larger regions of the brain, it has been
employed to evaluate the global brain NAA/Cr ratio,
which might be a good indicator for progression and
cognitive decline in MS [115]. Thus, measuring NAA/
Cr ratio in WM and GM within scan times of
20 min and TE of 144 ms, provided multi-slice EPSI
a particular clinical utility. Similarly, reduction of
NAA in GM of RRMS and SPMS groups was demon-
strated by using a volumetric spiral MRSI technique
[4] at a low static field of 1.5 T. A study by De
Stefano et al. confirmed that brain MR spectroscopic
data has a significant role in detecting neuoraxonal
damage caused by MS disease with decreased NAA/
Cr ratio [116] due to the consistent finding of de-
crease NAA signal being linked to axonal damage.
Moreover, acute lesions were found to have high Glu
levels; which might suggest a connection between the
axonal injury in active lesions and Glu excitotoxicity
[116]. Donadieu et al. used fast 3D-EPSI (TE: 20 ms)
at 3 T to acquire spectral maps of the complete brain
of MS patients (N = 19) and compared them to ageregions: [1] MS lesion, [2] CGM and [3] NAWM. The voxels are
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cated a reduction in NAA and Glx (−15 and −20%)
in GM, while mI was increased in WM of MS group
(+22%). A summary of the results of MRSI methods
are shown in Table 3.
Reproducibility of MRSI of MS patients
Reproducibility of fast MRSI techniques has not been
evaluated. It is important that MRSI techniques have
good reproducibility and recent studies have shown
good correlation between time points. Mostert et al.
tested MRSI reproducibility with stable MS patients
4 week apart and found good short term reproducibility
of NAA/Cr measurement [118]. Vafaeyan et al. also vali-
dated the reproducibility of NAA/Cr and NAA/Cho in
MS as they found high correlation of these ratios at
different time points [119].
Conclusions
In recent years, the evolution of MR technologies has
led to developments of brain 1H-MRS and clinical MR
imaging procedures which enabled the collection of
morphometric and biochemical information in a single
imaging session. There are a variety of 1H-MRS tech-
niques that are used to detect and evaluate the biochem-
ical changes of whole brain, where whole brain coverage
requires improving spatial resolution and SNR. Fast MRSI
is more suited to a clinical setting, mainly due to faster
acquisition time, improved SNR and spatial resolution.
The short acquisition time of fast MRSI requires
advanced and robust design in the hardware and soft-
ware systems to improve and modify sequences for these
techniques, making them more adaptable, especially
when there is a need to combine them with other accel-
eration techniques by either increasing field strength or
modifying coil design.
EPSI has brought about revolutionary improvement in
the technological capacity of MRSI, compared to con-
ventional MRSI methods. This development has im-
proved the time efficiency of data collection and
enhanced the recording brain metabolite distribution.
Data acquisition has seen the biggest improvement, with
speeds more than two to three times faster than that of
traditional MRSI methods. This has provided the oppor-
tunity for clinical research to be done on whole brain in
acquisition times of less than 16 min.
This article has shown the benefits and ability of the
EPSI to adapt to a diverse range of techniques, leading
to: flyback-EPSI, MEGA-EPSI, GRAPPA-EPSI, SENSE-
EPSI 1H-MRSI techniques and 2D and 3D echo-planar
techniques. This also enables the detection of J-coupled
brain metabolites like: GABA, Glu, Gln and mI. More-
over, it can be concluded that the echo-planar imaging
sequence has proven to be a successful and acceleratedtechnique in clinical studies not only in multiple scler-
osis [4] but also in Parkinson’s disease [1], Alzheimer’s
disease [2] and stroke [3].
In vivo spectroscopy has the potential to play an im-
portant role in biomarker discovery and disease activity
prediction in MS. MRSI studies confirmed that NAA/Cr
can distinguish MS from HCs independent from the
ROI. NAA can also be a potential marker of neuronal
function in NAWM, CGM for different clinical groups
identifying the progressive stage of the disease. Longitu-
dinal studies with techniques applicable in clinical
setting are required to determine if MRSI can close the
gap in MRI imaging by defining the disease course for
the individual patient. The larger ROI afforded by MRSI
compared to conventional MRS has provided evaluations
of neurometabolite changes to be assessed across a
much larger area, thereby assessing whole brain patho-
logical changes occurring in MS. The improvements in
achieving shorter acquisition times for MRSI now
provide a greater likelihood of clinical application of
these techniques.
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